Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Roche Gets Speedy China Approval for New Lung Cancer Treatment

publication date: Aug 21, 2018

Roche received marketing authorization from the China National Drug Administration for Alecensa (alectinib) as a first-line treatment for ALK-positive non-small cell lung cancer. The company noted the approval came just eight and nine months after EU and US approvals, a speedy priority review process. Alecensa more than tripled progression-free-survival in Phase III trials, compared to Xalkori (crizotinib), a Pfizer drug. More details....

Stock Symbols: (VX: ROG) (NYSE: PFE)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.